on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
ADCendo is a biotech start-up company based on a novel cancer drug, invented by the company founders. The drug is an antibody-drug conjugate (ADC), targeting cancer types that currently cannot be cured. • Unmet need: Targeted therapy against sarcomas (primary bone cancer and soft tissue tumors), glioblastomas (GBM; the most malignant brain tumors) and certain types of leukemia • Product: Antibody-drug-conjugate (ADC) against the collagen receptor uPARAP , with proven in vitro efficiency against cell lines of the cancer types mentioned, and convincing in vivo proof of concept in a model of solid cancer. For sarcomas, no efficient treatment exists if metastasis has occurred. GBM is an extremely aggressive type of cancer and is incurable. For leukemia, some sub-types can be treated but relapse is common, mortality still high and additional treatment options are strongly needed.
Actual status: • Proof of concept of receptor-specific and potent killing of sarcoma, GBM and leukemic cells has been obtained in vitro • Very high efficiency and wide window of specificity • A 100 % cure rate obtained in mice with transplanted human tumor cells, with no adverse effects observed • Priority-founding patent applications filed • Commercialization process supported by pre-seed grant from Novo Seeds, Denmark • Company ADCendo has been founded • Ideal scientific and clinical network, with founders based in university and hospital positions • Contact established with key opinion leaders • Pre-clinical and early clinical development plan in place
Paul Biondi is currently senior vice president, Head of Business Development for Bristol-Myers Squibb responsible for leading the development of strategic partnerships and pursuing external scientific innovations across commercial, development, discovery and technology platforms to complement the company’s internal R&D pipeline. With deep knowledge of the company’s R&D strategy and portfolio, strong business expertise and understanding of the healthcare landscape, Paul is focused on external innovation that helps Bristol-Myers Squibb develop and deliver transformational medicines for patients with serious diseases.
Prior to this recent appointment, Paul led the R&D Operations organization at Bristol-Myers Squibb for 10 years working for the Head of R&D at BMS and providing strategic insights and operational excellence to enhance the performance of the R&D organization. As head of R&D Operations he was responsible for optimizing the delivery of the company’s pipeline, managing the company’s R&D portfolio and delivering early- and late-stage clinical operations. He also had responsibility for cross R&D efforts around strategy, analytics, continuous improvement, learning and collaboration. In this role, Paul worked closely with the Business Development leaders in formulating portfolio and disease specific strategies as well as overseeing all integrations of any scientific assets or R&D companies.
Biondi joined Bristol-Myers Squibb in 2002 and was appointed vice president of R&D
Operations when it was formed in May 2005. He was promoted to senior vice president of R&D Operations in 2010. Paul was appointed senior vice president, Head of Business Development in October 2015.
Biondi holds a bachelor’s degree in government and economics from Dartmouth College and an M.B.A. from J.L. Kellogg School of Management at Northwestern University.
Kristen Bridge
Bristol-Myers Squibb
Head of Business Development Strategy and Operations
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
Company Profile
DataHow AG is a spin-off company from ETH Zurich specialized in data analytics and process modeling for the process industry with a particular focus on the production of biopharmaceuticals.
We offer digital solutions and consulting for process screening, monitoring, optimization, control and scale-up. Our goal is to reduce the effort, risks and costs in process development and manufacturing as well as to gain deep understanding of the complex processes.
DataHow emerged in 2017 from the research group of Prof. Morbidelli at ETH Zurich based on the activities of Dr. Alessandro Butté, Michael Sokolov and Fabian Feidl.
Responsive Web Design powered by 